Wellbutrin
Executive Summary
Burroughs Wellcome is reconsidering whether to continue safety evaluations of the anxiolytic, and is holding discussions with FDA. Firm withdrew the drug from the market in March following reports of a high incidence of seizures in a study of bulemic patients. FDA's Psychopharmacologic Drugs Advisory Committee agreed in April that a study proposed by Burroughs Wellcome comparing Wellbutrin (bupropion HCl) to imipramine (Ciba Geigy's Tofranil) would be adequate to assess the safety of Wellbutrin.